http://www3.interscience.wiley.com/cgi-bin/abstract/104526758/ABSTRACT- www3.interscience.wiley.com/cgi-bin/abstract/104526758/ABSTRACT
FDA Agrees to File NDA for Xinlay™ in the Treatment of Metastatic ... FDA Agrees to File NDA for Xinlay™ in the Treatment of Metastatic Hormone-Refractory Prostate Cancer © CancerConsultants.com; http://www.CancerConsultants.com Cancer Information Specialists ... - www.411cancer.com/syndication/veContent.jsp?ArticleID=prostate_feb05_11&ArticleTypeID=NEWS
New Drug Irofulven is Active against Metastatic Hormone-Refractory ... New Drug Irofulven is Active against Metastatic Hormone-Refractory Prostate Cancer © CancerConsultants.com; http://www.CancerConsultants.com Cancer Information Specialists, leading the way to ... - www.411cancer.com/syndication/veContent.jsp?ArticleID=prostate_feb05_3&ArticleTypeID=NEWS
Advance Hormone Refractory Prostate Cancer - Page 4www.cpdr.org: US TOO Newsletter - ... Hormone Refractory Prostate Cancer - Celestia S. Higano, M.D. | Home | Newsletter (P<.000 1). Although PSA was not an endpoint of the trial, 44% had a PSA ... - www.cpdr.org/ustoo/aug2000/hormone/hormone4.shtml
Hormone Refractory Prostate Cancer - hrpca.org ... service to men, women, and their caregivers who are fighting hormone-refractory prostate cancer (hrpca). This web site and the on-line support list are managed ... A phase I, pharmacokinetic and biologic correlative study of G3139 ... ... study of G3139 (Bcl-2 antisense oligonucleotide) and Docetaxel in patients with hormone-refractory prostate cancer (HRPC). AW Tolcher 1,2 , J Kuhn 1 , J Basler 2 , L Ochoa 1 , G Schwartz 3 , A Patnaik 1 , L ... - www.aacr.org/newdrugs00/527.html
Phase I and II trials of 1alpha-hydroxyvitamin D2 in patients with ... ... AACR. 112 Phase I and II trials of 1 -hydroxyvitamin D 2 in patients with metastatic hormone-refractory prostate cancer. Bailey, HH, Ripple, G, Horvath, D, Staab, MJ, Alberti, D, Arzoomanian, RZ, Miller, K ... - www.aacr.org/newdrugs00/112.html
National Cancer Institute - Newly Approved Cancer Treatments ... with prednisone for the treatment of metastatic, androgen-independent (hormone-refractory) prostate cancer. Safety and efficacy were demonstrated in TAX327, a randomized, multicenter global clinical ... - cancer.gov/clinicaltrials/developments/newly-approved-treatments/allpages/print
Phase 2, multicenter, randomized, double-blind, safety ... ... study of two doses of 2-methoxyestradiol administered orally in patients with hormone refractory prostate cancer George Wilding, Christopher Sweeney, David M.King, Dorothea Horvath, Mary Jane ... - www.entremed.com/download/posters/ASCO_POSTER_wilding.pdf
- PDF file
New Drug Irofulven is Active against Metastatic Hormone-Refractory ... ... New Drug Irofulven is Active against Metastatic Hormone-Refractory Prostate Cancer According to the results of a recent phase 2 study published in the American Journal of Clinical Oncology , the new ... - patient.cancerconsultants.com/prostate_cancer_news.aspx?id=33281
|
